FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and ...
-- Patented SelectFlex(TM) Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature -- System enables biaxial approach, ...
MIAMI BEACH, Fla.--(BUSINESS WIRE)--RIST Neurovascular, Inc., a neuro-interventional medtech company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market ...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global neurovascular devices market is estimated to be valued at US$ 2,340.4 million in 2020 and is expected to exhibit a CAGR of 4 ...
Cerus Endovascular looks to stand out from the other companies that make up the intracranial aneurysm treatment market. The Fremont, CA-based company has won breakthrough device designation for the ...
Cerus Endovascular Ltd has received CE Mark approval for the commercial sale of its Contour Neurovascular System for the treatment of intra-cranial aneurysms (IAs) across the European Union (EU). The ...
The U.S. FDA has granted breakthrough device designation to Cerus Endovascular Ltd. for its Contour neurovascular system for the treatment of intracranial aneurysms. The company is targeting the ...
Patented SelectFlex™ Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature System enables biaxial approach, regardless of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results